← Leaderboards
Frederick L Hall
University Of Southern California
$290,343
Attributed
$290,343
Total exposure
2
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $145.3K · FY2006–07$200K$150K$100K$50K$0
'06
'07
Funding mix
By agency
FDA$290,343 · 1
NIH$0 · 1
By mechanism
R01$290,343 · 1
P20$0 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Southern California
Same institution · by research overlap
- Arthur W Toga$135,966,223
- Caryn Lerman$95,133,528
- Jeffrey S Weber$20,866,039
- Timothy J. Triche$21,258,785
- Alexandra M Levine$34,706,653
Others in their field
Top investigators on “Alphaherpesvirinae”
- Gregory Allan Smith · Albert Einstein College Of Medicine$4,780,726
- Bernard Roizman · University Of Alabama At Birmingham$4,673,409
- Donald M Coen · University Of Pennsylvania$4,391,905
- Barry T. Rouse · University Of Tennessee Knoxville$2,726,346
- David J. Fink · University Of Pittsburgh At Pittsburgh$2,481,223
- Saul J Silverstein · Columbia University Health Sciences$2,460,770
Research focus
AlphaherpesvirinaeAntigen PresentationAntineoplasticsAutoradiographyBiological Signal TransductionColon NeoplasmsColony Stimulating FactorDisease /Disorder ModelGene ExpressionGene TherapyImmunocytochemistryLaboratory MouseNeoplasm /Cancer ImmunotherapyNeoplasm /Cancer Remission /RegressionNeoplasm /Cancer VaccineNonhuman Therapy EvaluationPolymerase Chain ReactionPositron Emission TomographyProtein EngineeringRadiotracerRetroviridaeSarcomaThymidine KinaseTissue /Cell Culture
Grant awards (4)
Phase I Clinical Trial Using Rexin-G for Pancreatic Can*$145,349
R01 · FY2007 · FD · contact PI
Phase I Clinical Trial Using Rexin-G for Pancreatic Can*$144,994
R01 · FY2006 · FD · contact PI
TARGETED RETROVIRAL VECTORS FOR CANCER IMMUNOTHERAPY$0
P20 · FY2002 · CA
TARGETED RETROVIRAL VECTORS FOR CANCER IMMUNOTHERAPY$0
P20 · FY2001 · CA